drugset / Trial / NCT05742425
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
Phase 2
Recruiting
30 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Changxing People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Multicentric randomised trial. The goal of this clinical research study is to evaluate the efficacy and safety of serplulimab combined with FOLFIRI+bevacizumab in the treatment of pMMR/Ras/BRAF wild-type unresectable peritoneal metastasis of colon cancer.
Timeline
- Start
- 2023-03
- Primary completion
- 2028-03
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Serplulimab | Monoclonal antibody | — | — |